The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
© Winger et al; licensee BioMed Central Ltd. 2009
Received: 08 January 2009
Accepted: 24 February 2009
Published: 24 February 2009
Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.
We examined the inhibition of NQO2 activity by the Abl kinase inhibitors imatinib, nilotinib, and dasatinib, and obtained IC50 values of 80 nM, 380 nM, and >100 μM, respectively. Using electronic absorption spectroscopy, we show that imatinib binding results in a perturbation of the protein environment around the flavin prosthetic group in NQO2. We have determined the crystal structure of the complex of imatinib with human NQO2 at 1.75 Å resolution, which reveals that imatinib binds in the enzyme active site, adjacent to the flavin isoalloxazine ring. We find that phosphorylation of NQO2 has little effect on enzyme activity and is therefore likely to regulate other aspects of NQO2 function.
The structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits NQO2 activity by competing with substrate for the active site. The overall conformation of imatinib when bound to NQO2 resembles the folded conformation observed in some kinase complexes. Interactions made by imatinib with residues at the rim of the active site provide an explanation for the binding selectivity of NQO2 for imatinib, nilotinib, and dasatinib. These interactions also provide a rationale for the lack of inhibition of the related oxidoreductase NQO1 by these compounds. Taken together, these studies provide insight into the mechanism of NQO2 inhibition by imatinib, with potential implications for drug design and treatment of chronic myelogenous leukemia in patients.
A series of biochemical and structural studies have elucidated the mechanisms responsible for the inhibition of Abl by imatinib. Protein kinases generally adopt similar active conformations, but can differ significantly in their inactive conformations; imatinib inhibits Abl specifically by binding to an inactive kinase domain conformation that is characteristic of Abl [6–8]. The Kit kinase domain also adopts an inactive conformation when bound to imatinib, and this conformation resembles that of Abl bound to imatinib [9, 10]. Kit and PDGFR are now therapeutic targets of imatinib for tumor types in which they are in a deregulated state [11, 12].
Imatinib displays excellent efficacy and minimal side effects in clinical studies with CML patients [13, 14], and now represents the frontline therapy for CML . However, patients in advanced stages of the disease develop resistance to imatinib treatment, due to the acquisition of mutations in the Abl kinase domain that render the protein insensitive to this inhibitor [16, 17]. Second-generation drugs such as nilotinib [18, 19] and dasatinib  (Figure 1A) have been developed that are able to target most, but not all, imatinib-resistance mutations. Currently, third-generation therapeutic agents are in development or clinical evaluation.
A major goal in the further development of kinase inhibitors is to maintain a degree of specificity similar to that of imatinib for Abl, thereby minimizing potential side effects from off-target interactions. Thus, to identify potential secondary targets of these inhibitors, recent studies have focused on chemical proteomics screens for drug-interactors [21, 22]. Briefly, the screens involve the generation of matrix-linked inhibitors that are used to pull down interacting proteins, which are then identified by mass spectrometry and validated by binding and activity studies. This approach has been pursued with imatinib and the second-generation inhibitors nilotinib, dasatinib, and bosutinib. In addition to the known targets of these inhibitors, additional kinase targets were identified. For imatinib, the screens also identified a surprising non-kinase target, the oxidoreductase NQO2, which also was shown to be a target of the second-generation inhibitor nilotinib but not dasatinib or bosutinib [21, 22].
NQO2 is a cytosolic flavoprotein that carries out the 2-electron reduction of quinones using electron donors such as nicotinamide riboside (NRH). It is one of two closely related cellular quinone reductases (the other being NQO1) and is thought to be involved in metabolic reduction and xenobiotic detoxification [23, 24], although its precise physiological role remains uncertain . Interestingly, NQO2 is highly expressed in myeloid cells, the targets of imatinib in CML anticancer therapy, and RNAi knockdown of NQO2 in K562 cells, an immortalized Bcr-Abl-positive CML cell line, resulted in reduced proliferation rates . The phosphorylation of NQO2 on a serine residue in K562 cells was observed , suggesting potential regulation of the activity of the enzyme by phosphorylation.
Imatinib and nilotinib inhibited the NQO2-mediated reduction of the anticancer drug mitomycin C, with IC50 values of 1 μM for imatinib and 1.8 μM for nilotinib . Another set of experiments demonstrated competitive inhibition by imatinib of the NQO2-mediated reduction of menadione (vitamin K3) with a Ki of 39 nM, in line with an IC50 value of 43 nM obtained by competitive binding assay . These data, together with the observation that imatinib levels reach ~1 μM in the serum of patients [14, 27], imply that NQO2 inhibition occurs in imatinib-treated CML patients, raising the possibility that NQO2 inhibition may contribute to the overall pharmacological effects of these drugs.
The exact mechanism by which NQO2 is inhibited by imatinib is unknown. Neither chemical proteomics study detected turnover of imatinib by NQO2. One study proposed that imatinib inhibits NQO2 activity via competition with the FAD cofactor for binding to the enzyme , while the other study reported competitive inhibition with respect to the substrate menadione .
Here, we report studies undertaken to further understand the structural basis for the molecular mechanism by which imatinib binds to and inhibits NQO2. Spectroscopic measurements confirmed the direct binding of imatinib to NQO2, with concurrent changes in the flavin environment indicating that the FAD is not displaced by imatinib. We have solved the X-ray crystal structure of NQO2 bound to imatinib to 1.75 Å resolution, which shows that the drug is bound adjacent to the flavin isoalloxazine ring. The X-ray structure further provides an explanation for the binding specificity of NQO2 for imatinib and nilotinib, as well as for the effects of mutation of the reported phosphorylation sites on NQO2.
Results and discussion
Inhibition of NQO2 by imatinib and nilotinib
To assess the inhibition of NQO2 by imatinib, a continuous spectrophotometric assay was used. Briefly, the NQO2-mediated reduction of menadione to menadiol is coupled to the reduction of the dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by menadiol, resulting in an increase in absorbance at 590 nm. Nilotinib, dasatinib, and quercetin, a flavonoid NQO2 inhibitor that is also a non-specific kinase inhibitor , were included for comparison. As shown in Figure 1B, imatinib inhibited NQO2 activity with an IC50 value of 82 nM, approaching that observed for quercetin (42 nM). These values are in the same range as those determined previously [22, 28]. Nilotinib inhibited NQO2 activity with an IC50 value of 381 nM, while dasatinib did not inhibit NQO2 activity significantly at the concentrations tested (IC50 > 100 μM).
Binding of imatinib to NQO2
Structure of the NQO2-imatinib complex
Crystallographic data and refinement statistics
a = 100.3 Å, b = 100.3 Å, c = 104.9 Å
α = 90°, β = 90°, γ = 90°
I/σ (I) *
Free R test set (% of total data)
Monomers per asymmetric unit
Number of non-hydrogen atoms
Ligand (imatinib, FAD, MRD)
r.m.s. deviation, bond lengths (Å)
r.m.s. deviation, bond angles (Å)
Steric constraints prevent the bound imatinib from binding in an extended conformation, causing it to instead adopt a horseshoe shape that directs the methylbenzene, benzamide, and N-methylpiperazine rings (rings C, D and E) away from the active site and towards the solvent (Figure 4C). The imatinib N-methylpiperazine ring extends into solvent and forms crystal contacts with a third symmetry-related molecule.
The inhibitor makes no direct hydrogen bonds with the protein, although several water-mediated hydrogen bonds are observed. A water-mediated hydrogen bond is formed between Asn 161, which is positioned by a hydrogen-bonding interaction with Tyr 132, and the N3 nitrogen of the imatinib pyridine ring (ring A). The N8 and N13 nitrogen atoms of the imatinib 2-aminopyrimidine moiety (ring B) interact with a cluster of ordered waters (Figure 4B). A similar water cluster is also observed in several other NQO2-ligand complexes [26, 34], and such water-mediated interactions have been proposed to be important for NQO2 ligand recognition [31, 35].
Discrimination by NQO2 between imatinib, nilotinib and dasatinib
The imatinib binding mode we observe in our structure explains why NQO2 is inhibited by nilotinib, but not by dasatinib . Nilotinib contains a 4-pyridyl-2-phenylaminopyrimidine core (nilotinib rings A, B and C, Figure 1A), identical to that of imatinib, that can adopt a planar conformation and fit in the active site, and a similar amide-linked substituted phenyl ring (nilotinib ring D, Figure 1A), which likely also extends towards solvent from the active site. The modest reduction in affinity relative to imatinib may be due to the increased bulk and decreased flexibility of the nilotinib trifluoromethylbenzene and methylimidazole rings (nilotinib rings D and E, Figure 1A) compared to the benzamide and N-methylpiperazine rings of imatinib (imatinib rings D and E, Figure 1A). The chemical structure of dasatinib contains an aminopyrimidine core similar to that of imatinib and nilotinib (dasatinib ring B, Figure 1A), but the adjacent non-aromatic hydroxyethylpiperazine ring (dasatinib ring A, Figure 1A) cannot adopt the planar conformation necessary for stacking onto the flavin isoalloxazine ring. Dasatinib is unable to adopt a cis conformation (see the kinase discussion below for an explanation) around the bond between the aminopyrimidine and thiazole rings (dasatinib rings B and C, Figure 1A) that is capable of productive interaction with the rim of the active site.
Specificity of imatinib for NQO2 over NQO1
Comparison of the imatinib binding modes observed in NQO2 and in kinases
Ser 16 and Ser 20 are both located adjacent to the binding site for the FAD cofactor. Ser 20 is involved in recognition of the FAD adenine ring (Figure 8B), so mutation at this position might disrupt this interaction and reduce FAD binding affinity, resulting in the lower activities of the S20A and S20D mutants (Figure 8A). The side chain of Ser 16 forms a hydrogen bond with the main chain amide of Gly 19 and packs against the imidazole side chain of His 11, keeping the main chain of Ser 16 from blocking part of the FAD adenine binding site. The Ser 16 hydroxyl group is also close to the diphosphate moiety of the FAD (3.2 – 3.6 Å from the phosphate oxygen atoms to the Ser 16 Cβ atom) (Figure 8B). The S16A mutation might disrupt the hydrogen-bonding and van der Waals interactions necessary for proper formation of the adenine binding pocket, resulting in a decrease in FAD binding affinity similar to that caused by the Ser 20 mutations. The pronounced drop in activity of the S16D mutant (Figure 8A), as well as the observed loss of yellow color and partial monomerization, suggests loss of the FAD cofactor. Such cofactor loss might result from repulsion between the phosphate oxygen atoms of the FAD diphosphate moiety and the aspartate side chain of the S16D mutant, in addition to disruption of interactions necessary for proper formation of the adenine binding pocket.
What role could phosphorylation of NQO2 play in vivo? While the large decrease in the activity of the S16D mutant suggests that phosphorylation of this residue could mediate down-regulation of NQO2 activity, the buried nature of the Ser 16 side chain likely precludes it from being a target for phosphorylation in cells. Furthermore, studies have indicated that NQO2 is functional in K562 cells  – the same cells in which NQO2 was found to be phosphorylated , suggesting that phosphorylation of NQO2 is unlikely to be directly inactivating. Thus, it is more likely that the solvent-exposed Ser 20 is the site of NQO2 phosphoryation. The relatively minor effect of Ser 20 mutation on enzyme activity suggests that phosphorylation may regulate some other aspect of NQO2 function, rather than by directly affecting enzyme activity. It is worth noting that imatinib, and therefore Bcr-Abl inhibition, did not alter the phosphorylation of NQO2 on Ser 20 . Therefore, the kinase that phosphorylates NQO2 is unlikely to be a direct Bcr-Abl effector.
To date, numerous crystal structures of the flavoprotein oxidoreductase NQO2 in complex with quinones, natural products, and xenobiotics have been solved [26, 31, 34–37], and we report here the x-ray crystal structure of NQO2 bound to the leukemia drug imatinib, an inhibitor of Bcr-Abl. Our study has been motivated by the possibility that inhibitors of Bcr-Abl might also interact with unintended targets, and that these interactions may lead to side effects during drug treatment. The data reported in this work elucidate the mechanism of NQO2 inhibition by imatinib, and suggest that NQO2 is likely to be inhibited by imatinib at the 1-μM serum concentration typical in patients [14, 27]. The question remains as to what the physiological consequences of NQO2 inhibition by imatinib may be and whether they contribute to the efficacy of imatinib in treatment of CML. While it has been reported that RNAi knockdown of NQO2 or treatment with the polyphenol NQO2 inhibitor resveratrol results in a reduction of proliferation of Bcr-Abl-positive K562 cells , we failed to see any effect of NQO2 knockdown on K562 cell proliferation (data not shown). On the other hand, NQO2 knockout mice exhibit myeloid hyperplasia  and increased susceptibility to chemical carcinogenesis . Although these side effects have not been observed yet in CML patients treated with imatinib [48, 49], future studies on the effects of NQO2 inhibition on cellular function and the role of NQO2 in cancer initiation and progression may shed light on the possible physiological consequences of NQO2 inhibition by imatinib or nilotinib.
Expression and purification of recombinant NQO2
Full-length human NQO2 was cloned into the vector pETM30 (EMBL-Heidelberg, Protein Expression Facility), resulting in a His6-GST-NQO2 fusion protein with a TEV protease cleavage site between GST and NQO2. The construct was verified by sequencing and transformed into Tuner(DE3)pLysS cells (Novagen) for protein expression. Cells from 2 × 1 L expression cultures were harvested by centrifugation, and cells were resuspended in buffer A (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole). Cells were lysed by sonication, and the lysate was cleared by centrifugation at 200,000 g. The supernatant was applied to a 5 mL HisTrap FF column (GE Healthcare) equilibrated with buffer A, washed with buffer A until the absorbance at 280 nm was stable, and eluted with 250 mM imidazole in buffer A. The eluted yellow protein was desalted into buffer A and the His6-GST purification tag was cleaved off using TEV protease. The protease and His6-GST were removed from the NQO2 by passage back over the HisTrap column. NQO2 was desalted into buffer B (25 mM Tris-HCl pH 8.0, 25 mM NaCl) by concentration/dilution on a 5 K Amicon Ultrafree concentrator (Millipore) and loaded onto a 5 mL HighTrap Q HP column (GE Healthcare). Protein was eluted with a gradient of 0 – 500 mM NaCl in buffer B, and fractions containing NQO2 (as ascertained by SDS-PAGE) were pooled, concentrated on a 5 K Amicon Ultrafree concentrator, and stored at -20°C.
NQO2 activity assays
Activity of NQO2 was assayed using a continuous spectrophotometric assay, adapted from previously reported methods [22, 28], with menadione as substrate and 1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyrimidine (CCHP) as co-substrate. Reduction of the dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) was monitored at 590 nm using a SpectraMax M5 plate reader (Molecular Dynamics). Reaction were carried out at 30°C in 200 μl containing 25 mM Tris-HCl pH 7.5, 0.01% Tween-20, 0.18 mg/ml BSA, 1 μM FAD, 100 μM menadione, 0.134 mg/ml MTT, and 500 μM CCHP. Reactions were initiated by addition of 20 ng recombinant NQO2. For NQO2 inhibition assays, the respective inhibitors were pre-incubated with the recombinant NQO2 and reactions were started by the addition of substrate/co-substrate. Slopes of the absorption-time-diagram were used to calculate the specific activity. Each experiment was repeated twice.
Electronic absorption spectroscopy
Imatinib stocks were prepared in dimethyl sulfoxide (DMSO). NQO2 (18.3 μM) in 50 mM Tris-HCl pH 7.5 was mixed with imatinib (40 μM in 5% DMSO) or DMSO and placed in a quartz cuvette. Electronic absorption spectra were collected with a Cary 3E spectrophotometer (Varian) at 25°C. Data were collected over the range of 260–700 nm at 600 nm/min with a 1 nm data point interval. A buffer baseline was subtracted for each spectrum. Imatinib exhibits some absorption in this wavelength range (data not shown), so the buffer for the imatinib sample baseline also contained 40 μM imatinib. Difference spectra were obtained by subtraction of the spectrum for the sample containing NQO2 alone from the spectrum of the sample containing imatinib.
Crystallization and X-ray data collection
NQO2 was thawed and desalted into 50 mM Tris-HCl pH 8.0, by three cycles of concentration/dilution on a 5 K Amicon Ultrafree concentrator. Imatinib stocks were prepared in DMSO. The NQO2-imatinib complex was formed in a solution containing 50 mM Tris-HCl pH 8.0, 5 mM tris(2-carboxyethyl)phosphine, 1.15 mM NQO2, and 1.5 mM imatinib, with a final concentration of 5% DMSO. Crystals of the NQO2-imatinib complex were grown in hanging drops at 20°C using the vapor diffusion method. A volume of 1 μL of protein solution was mixed with an equal volume of reservoir solution [62% (4R, S)-2-methylpentane-2,4-diol (MPD) in 100 mM MES pH 6.0–6.2, 15 μM FAD] and allowed to equilibrate, and yellow rod-shaped crystals grew overnight. For X-ray diffraction experiments, crystals were transferred to a solution of mother liquor (which already contained the cryoprotectant MPD at a concentration of 62%), frozen, and stored in liquid nitrogen. Diffraction data were collected at the Advanced Light Source (Lawrence Berkeley National Laboratory) beamline 8.2.1. Reflections were processed in space group I422 with MOSFLM  and SCALA . The structure was determined with the molecular replacement program PHASER  using human NQO2 (PDB ID 1QR2)  as the search model. The structure was built using ARP/wARP , the model was improved using COOT , and refinement was carried out using PHENIX . Model quality was analyzed using MOLPROBITY , and figures were drawn using the software PYMOL . The atomic coordinates and structure factors have been deposited in the Protein Data Bank (3FW1).
We thank Sebastian Deindl, Meindert Lamers, Nicholas Levinson, Sonja Lorenz, Markus Seeliger, Ines Kaupe and Uwe Rix for valuable discussions, technical assistance, and critical reading of the manuscript. This work was supported in part by grant #P18737 of the Austrian Science Fund (FWF). The Advanced Light Source is supported by the U.S. Department of Energy under Contract DE-AC03-76SF00098 at the Lawrence Berkeley National Laboratory.
- Sawyers CL: Chronic myeloid leukemia. N Engl J Med 1999, 340(17):1330–1340.View ArticlePubMedGoogle Scholar
- Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247(4946):1079–1082.View ArticlePubMedGoogle Scholar
- Sawyers CL: Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Leukemia Lymphoma 1993, 11(Suppl 2):101–103.View ArticlePubMedGoogle Scholar
- Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105(7):2640–2653.View ArticlePubMedGoogle Scholar
- Hantschel O, Rix U, Superti-Furga G: Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia Lymphoma 2008, 49(4):615–619.View ArticlePubMedGoogle Scholar
- Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62(15):4236–4243.PubMedGoogle Scholar
- Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003, 112(6):859–871.View ArticlePubMedGoogle Scholar
- Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289(5486):1938–1942.View ArticlePubMedGoogle Scholar
- Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295(1):139–145.PubMedGoogle Scholar
- Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004, 279(30):31655–31663.View ArticlePubMedGoogle Scholar
- Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347(7):481–487.View ArticlePubMedGoogle Scholar
- Demetri GD, von Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472–480.View ArticlePubMedGoogle Scholar
- Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344(14):1038–1042.View ArticlePubMedGoogle Scholar
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031–1037.View ArticlePubMedGoogle Scholar
- Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408–2417.View ArticlePubMedGoogle Scholar
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531):876–880.View ArticlePubMedGoogle Scholar
- Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2):117–125.View ArticlePubMedGoogle Scholar
- Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2):129–141.View ArticlePubMedGoogle Scholar
- Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354(24):2542–2551.View ArticlePubMedGoogle Scholar
- Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47(27):6658–6661.View ArticlePubMedGoogle Scholar
- Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110(12):4055–4063.View ArticlePubMedGoogle Scholar
- Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, et al.: Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25(9):1035–1044.View ArticlePubMedGoogle Scholar
- Celli CM, Tran N, Knox R, Jaiswal AK: NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006, 72(3):366.View ArticlePubMedGoogle Scholar
- Gong X, Gutala R, Jaiswal AK: Quinone Oxidoreductases and Vitamin K Metabolism. In Vitam Horm. Volume 78. Edited by: Litwack G. Academic Press; 2008:85–101.Google Scholar
- Vella F, Ferry G, Delagrange P, Boutin JA: NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005, 71(1–2):1–12.View ArticlePubMedGoogle Scholar
- Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43(36):11417–11426.PubMed CentralView ArticlePubMedGoogle Scholar
- Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, et al.: Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9(2):625–632.PubMedGoogle Scholar
- Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, Deng PS, Chen S: Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997, 347(2):221–228.View ArticlePubMedGoogle Scholar
- Palfey BA, Massey V: Flavin-Dependent Enzymes. In Comprehensive biological catalysis: a mechanistic reference. Volume 3. Edited by: Sinnott M. San Diego: Academic Press; 1998:83–154.Google Scholar
- Whitby LG: A new method for preparing flavin-adenine dinucleotide. Biochem J 1953, 54(3):437–442.PubMed CentralView ArticlePubMedGoogle Scholar
- Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM: Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 1999, 38(31):9881–9886.View ArticlePubMedGoogle Scholar
- Brunger AT: Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355(6359):472–475.View ArticlePubMedGoogle Scholar
- Zhao Q, Yang XL, Holtzclaw WD, Talalay P: Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). P Natl Acad Sci U S A 1997, 94(5):1669–1674.View ArticleGoogle Scholar
- AbuKhader M, Heap J, De Matteis C, Kellam B, Doughty SW, Minton N, Paoli M: Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex. J Med Chem 2005, 48(24):7714–7719.View ArticlePubMedGoogle Scholar
- Calamini B, Santarsiero BD, Boutin JA, Mesecar AD: Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J 2008, 413(1):81–91.PubMed CentralView ArticlePubMedGoogle Scholar
- Fu Y, Buryanovskyy L, Zhang Z: Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem Biophys Res Commun 2005, 336(1):332–338.View ArticlePubMedGoogle Scholar
- Fu Y, Buryanovskyy L, Zhang Z: Quinone reductase 2 is a catechol quinone reductase. J Biol Chem 2008, 283(35):23829–23835.PubMed CentralView ArticlePubMedGoogle Scholar
- Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, Amzel LM: Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci U S A 2000, 97(7):3177–3182.PubMed CentralView ArticlePubMedGoogle Scholar
- Liao S, Dulaney JT, Williams-Ashman HG: Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide. J Biol Chem 1962, 237(9):2981–2987.PubMedGoogle Scholar
- Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW: Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D 2007, 63(Pt 1):80–93.PubMed CentralView ArticlePubMedGoogle Scholar
- Jacobs M, Caron P, Hare B: Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins 2008, 70(4):1451–1460.View ArticlePubMedGoogle Scholar
- Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J: c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 2007, 15(3):299–311.View ArticlePubMedGoogle Scholar
- Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2):129–141.View ArticlePubMedGoogle Scholar
- Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, et al.: A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004, 279(53):55827–55832.View ArticlePubMedGoogle Scholar
- Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T: The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005, 13(6):861–871.View ArticlePubMedGoogle Scholar
- Long DJ 2nd, Iskander K, Gaikwad A, Arin M, Roop DR, Knox R, Barrios R, Jaiswal AK: Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002, 277(48):46131–46139.View ArticlePubMedGoogle Scholar
- Iskander K, Paquet M, Brayton C, Jaiswal AK: Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004, 64(17):5925–5928.View ArticlePubMedGoogle Scholar
- Pilot PR, Sablinska K, Owen S, Hatfield A: Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006, 20(1):148. author reply 149View ArticlePubMedGoogle Scholar
- Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, et al.: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008, 111(3):1039–1043.View ArticlePubMedGoogle Scholar
- Leslie AGW: Recent changes to the MOSFLM package for processing film and image plate data. In Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography. Volume 26. Warrington LD, UK; 1992.Google Scholar
- The CCP4 suite: programs for protein crystallography Acta Crystallogr D 1994, 50(Pt 5):760–763.
- McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ: Likelihood-enhanced fast translation functions. Acta Crystallogr D 2005, 61: 458–464.View ArticlePubMedGoogle Scholar
- Perrakis A, Morris R, Lamzin VS: Automated protein model building combined with iterative structure refinement. Nat Struct Biol 1999, 6(5):458–463.View ArticlePubMedGoogle Scholar
- Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D 2004, 60: 2126–2132.View ArticlePubMedGoogle Scholar
- Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC: PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D 2002, 58: 1948–1954.View ArticlePubMedGoogle Scholar
- Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, et al.: MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007, (35 Web Server):W375–383.Google Scholar
- The PyMOL Molecular Graphics System[http://pymol.sourceforge.net/]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.